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Theoretically, harnessing the brain’s own endogenous plasticity mechanisms could serve to alter both inter-
nal states and external behavior in a therapeutic manner.If I were to describe a future therapy
for chronic, relapsing neuropsychiatric
diseases where patients with anxiety,
depression, or addiction could receive a
painless treatment over a few days and
emerge permanently cured without any
undesirable side-effects, you might think
this was science fiction. This scenario
might seem fanciful in light of our current
go-to strategies for treatment, which
involve systemically administered drugs
that bind to receptors throughout thebrain
and body. For the past few decades,
progress in the medical treatment of
neuropsychiatric disease states has
been incremental. In our modern era,
safety is a chief concern, somedicine typi-
cally follows science. There is good cause
for caution, and scientific understanding
should precede the medical treatment of
brain disease. But how far must available
treatments trail behind scientific insight?
The Path to Where We Are Now
In terms of first-line therapies, we are still
making use of technologies and funda-
mental principles identified nearly a
century ago, such as pharmacological
agents. While new drugs are steadily be-
ing identified, the majority of these are
variants of existing compounds. Other
therapies, usually only used when pa-
tients are resistant to drug treatments,
include electroconvulsive therapy (ECT)
and deep-brain stimulation (DBS). ECT
has been used to treat depressed patients
for nearly 80 years. DBS has a slightly
shorter history but has been used since
the 1980s to treat tremors associated
with Parkinson’s disease (Brice and
McLellan, 1980). More recently, DBS has
been used to treat neuropsychiatric disor-
ders such as depression (Mayberg et al.,
2005). Despite evidence of superior effi-cacy, ECT and DBS are not first-line
treatments because of the risks and
side-effects. ECT delivers electric shocks
to induce seizures, and side-effects
ranging from tissue and skeletal injuries
to cardiovascular problems, as well as
impairments in memory and cognition,
have been reported. DBS requires an
invasive surgery that inevitably incurs
some damage to brain tissue.
In contrast to medicine, the progress in
neuroscience research has been acceler-
ating at an explosive pace in the past two
decades. New technological develop-
ments have ushered in a new era for un-
derstanding the brain. While the 1990s
introduced the power of multiphoton im-
aging along with glutamate uncaging, an
approach that allows the activation of in-
dividual dendritic spines, this approach
was largely reserved for the scientific
elite—only those in the upper echelon of
funding or those with access to premium
facilities. By the turn of the millennium,
an extraordinary level of spatial precision
had been achieved with multiphoton im-
aging (Denk et al., 1990), a strong com-
munity had formed in elucidating the
fundamental principles in synaptic plas-
ticity (Malenka and Bear, 2004; Turri-
giano, 2012), and the visualization of
certain cell types using fluorescent pro-
teins powerfully transformed our ability
to observe a plethora of biological pro-
cesses (Tsien, 1998).
In terms of manipulating the activity
of neural circuit components to reveal
causal relationships with behavior, opto-
genetic tools broke open the flood gates
by making the ability to activate or inhibit
specific cells and even populations of
synapseswithmillisecond precision avail-
able to even the modestly funded
researcher (Adamantidis et al., 2007; Boy-Neuron 83, Sepden et al., 2005; Tye and Deisseroth,
2012). With the recent proliferation of
studies demonstrating that acutemodula-
tion of synaptic transmission can produce
acute changes in behavior, we are well
positioned to combine this knowledge
base with our understanding of synaptic
plasticity. Given that we can alter trans-
mission at specific synapses (Stuber
et al., 2011; Tye et al., 2011), can we
induce plasticity and therefore induce
long-lasting changes in behavior? By
establishing a new baseline level of syn-
aptic transmission, we inevitably influ-
ence the downstream network.
Foundation for the Future
In terms of looking forward, toward a new
era of therapy, neuroscience research has
already begun a strong shift from general
pharmacology to a circuit-based under-
standing of how the brain gives rise to
behavior.
Hebbian plasticity mechanisms such as
long-term potentiation (LTP) and long-
term depression (LTD) have been identi-
fied as the cellular bases for learning
and memory. Experiments demonstrating
that ablating select neurons involved in
the ‘‘memory engram’’ impaired memory
formation and retrieval have also provided
key insights toward how memories are
stored in the brain (Han et al., 2009;
Koya et al., 2009). Conversely, activating
ensembles of neurons that encode an
associative memory can elicit behaviors
that suggest the animal is recalling that
memory (Garner et al., 2012; Liu et al.,
2012). However, these experiments have
involved the modulation of ensembles of
neurons, rather than populations of syn-
apses. More recently the explicit induc-
tion of LTP and LTD has been shown to
enable experimenters to ‘‘toggle’’ thetember 17, 2014 ª2014 Elsevier Inc. 1259
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et al., 2014) or to reverse drug-induced
behaviors (Pascoli et al., 2012); even
further, it has shown that this could occur
in an input-specific manner (Pascoli et al.,
2014).
Homeostatic plasticity mechanisms are
generally conceptualized to serve as a
stabilizing force in a highly plastic system
to keep synapses within a functional dy-
namic range and prevent the overexcita-
tion (or inhibition) that could occur with
Hebbian plasticity mechanisms (Turri-
giano, 2012). In contrast to Hebbian plas-
ticity, which typically underlies learning
about discrete stimuli, contexts, or experi-
ences and has relevance to disease states
such as PTSD or drug abuse, homeostatic
plasticity may be more relevant to chronic
neuropsychiatric disease states that are
independent of learning per se, such as
anxiety or depression. Indeed, both phar-
macologic and optogenetic-mediated
sustained activation induced homeostatic
plasticity that reduced depression-related
behaviors in a mouse model (Friedman
et al., 2014).
The Road Forward
Based on these exciting studies that have
used optogenetic tools to induce Hebbian
or homeostatic forms of plasticity in vivo
to alter subsequent behavior, we can
now ask the question of whether an
acutely induced manipulation of synaptic
strength could produce long-lasting—or
even permanent—changes in behavior.
While these studies have broken new
ground, we have much work to do in
terms of laying down a solid foundation
for a new paradigm for therapy. New
questions can now be asked and
answered:
What are the best parameters for
inducing a change to a stable ‘‘new base-
line’’? There are many populations of
synapses to probe, and many types of
plasticity that can occur, so answering
this question will require the systematic
investigation of various circuit connec-
tions, behavioral readouts, plasticity in-
duction protocols, and time points for
testing. In essence, painstaking optimiza-
tion is required to identify the briefest
treatment period and the longest, most
robust, and most stable therapeutic
effect. Importantly, different circuits may
have unique optimal parameters.1260 Neuron 83, September 17, 2014 ª2014What does plasticity at a given popula-
tion of synapses do to the rest of the
circuit? While there have been major
advances in terms of high-density record-
ings in animal models along with a new
focus on ‘‘big data’’ sets, achieving a
complete answer in a noninvasive manner
in the human brain is not yet possible,
though efforts toward this goal have
been made. Much work remains to be
done in terms of the ultrastructural char-
acterization of all the neurons in the brain.
Even if the entirety of anatomical connec-
tions were known, the functional rele-
vance in terms of behavior represents an
even more formidable task given the
vast parameter space. For now, we can
build upon acute manipulations of
synaptic transmission and observe how
changes in synaptic transmission or the
strength of certain synapses impacts ac-
tivity in a subset of neurons in the associ-
ated circuit, and even this represents a
great challenge that will involve the efforts
of many research groups.
How could plasticity at specific popula-
tions of synapses be induced safely and
noninvasively in humans? This is the
most important, yet most challenging,
question to answer. The first step is to
capitalize on powerful, but invasive,
manipulations in animals to establish
a comprehensive characterization of
various targets, and the relative potency
and specific behavioral and cognitive
changes that occur when plasticity is
induced at a given neural circuit locus.
Once ideal targets have been identified,
translation to humans could occur using
a hybrid of stimulus presentations and
cognitive behavioral therapy, and nonin-
vasive manipulation of neural activity at
specific sites could be used to achieve
site-specific plasticity. While many of
these tools are still in development and/
or require further optimization, transcra-
nial magnetic stimulation (TMS) as a
technique for noninvasive, transient
manipulation of neural activity shows
promise in inducing plasticity and chang-
ing subsequent behavior (Gorelick et al.,
2014). However, these approaches do
not allow for the cell-type- and projec-
tion-specific precision of optogenetic
manipulations. While the toolbox of opsin
variants is growing, and the use of red-
shifted opsins could indeed sidestep the
necessity for implanting an optical fiberElsevier Inc.into brain tissue, the greater concern with
respect to safety is the expression strat-
egy.Most viruses showsome toxicity after
long periods of expression, and towarrant
use in humans, nontoxic expression must
be demonstrated on the order of at least
ten years or so. Thus, the winning strategy
for translation to humans remains to be
determined, and improvements in the
penetration and specificity of tools such
as TMS and the development of nontoxic
viral vectors will both take time to develop
and test. Other solutionswill probably sur-
face in thecomingdecade,but admittedly,
this represents the greatest challenge in a
shift toward circuit-based therapeutics.
And then there are other questions. In
the case that science and technology tri-
umph, what are the ethical considerations
for neural circuit reprogramming? What
elseneeds tohappen tomake thisa reality?
In addition to the scientific, technological,
and optimization challenges discussed
above, there is the issue of inertia. Drugs
have had a very long history of medical
use. For ailments of the body, they will
probably remain the first-line therapy for
the foreseeable future. Ailments of the
brain represent an entirely different beast,
and first-line treatments may very well
change as we embark on this ‘‘golden
era’’ in neuroscience research.
Translation or Reverse Translation?
Perhaps the concept of neural circuit re-
programming as a more effective strategy
for mental health treatment is not so un-
believable, or even so new, after all.
Another perspective could be that this is
a reverse translational concept, confirm-
ing theories that plasticity is the mecha-
nism mediating the therapeutic effect of
antidepressant treatments, from drugs to
ECT. Whether you believe that neural cir-
cuit reprogramming as a strategy for ther-
apy represents a major paradigm shift or
an improvement on a crude but effective
approach, a shift toward circuit-based di-
agnostics and treatments has the poten-
tial to transform the quality of mental
health treatment.
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